Primary cutaneous large B-cell lymphoma, leg-type (PCLBCL-LT) is the most aggressive
primary cutaneous B-cell lymphoma (PCBCL). Tumor microenvironment has a crucial role
in tumor development, and tumor-infiltrating lymphocytes (TILs) can be targeted by
immunotherapies. We characterized TILs in 20 PCBCLs to identify the tumor microenvironment
features associated with clinical outcomes. We developed a seven‒multiplex immunofluorescence
panel using Opal staining and image analysis using HALO software. In PCLBCL-LT, TILs
were sparsely intermingled within tumor infiltrate in contrast to those in indolent
PCBCL where TILs were scattered around tumor nodule edges with variable tumor infiltration.
In PCLBCL-LT, TILs were composed of CD8 and CD4, whereas CD4 was predominant in indolent
PCBCL. Proliferative TILs (CD3+Ki-67+ cells) were more abundant in PCLBCL-LT (P = 0.0036) than in indolent PCBCL. In PCLBCL-LT, proliferative TILs' abundance tended
to be associated with better progression-free survival. These data were confirmed
in a second independent cohort of 23 cases showing that proliferative TILs were more
abundant in PCLBCL-LT (P = 0.0205) and that in PCLBCL-LT, high CD3+Ki-67+ cell density was associated with
better progression-free survival (P = 0.002). These distinct TILs composition and distribution among PCBCL suggest that
proliferative T lymphocytes represent a good prognostic factor in PCLBCL-LT and that
stimulating their functions may represent a therapeutic approach.
Abbreviations:
ABC-DLBCL (activated B-cell diffuse large B-cell lymphoma), DLBCL (diffuse large B-cell lymphoma), mIF (multiplex immunofluorescence), OS (overall survival), PCBCL (primary cutaneous B-cell lymphoma), PCFCL (primary cutaneous follicle center lymphoma), PCLBCL-LT (primary cutaneous diffuse large B-cell lymphoma, leg type), PFS (progression-free survival), PCMZL (primary cutaneous marginal zone lymphoma), TIL (tumor-infiltrating lymphocyte), TME (tumor microenvironment)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Investigative DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma.N Engl J Med. 2015; 372: 311-319
- Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study.J Clin Oncol. 2019; 37: 481-489
- Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.Haematologica. 2021; 106: 718-729
- Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.Lung Cancer. 2018; 117: 73-79
- Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases.Am J Surg Pathol. 2019; 43: 1403-1412
- Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma.Leuk Lymphoma. 2021; 62: 76-85
- Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.Histopathology. 2015; 67: 625-635
- Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses.Clin Cancer Res. 2007; 13: 6666-6672
- Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CARD).Cytometry. 1996; 23: 48-53
- Targetable genetic features of primary testicular and primary central nervous system lymphomas.Blood. 2016; 127: 869-881
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med. 2018; 24 ([published corrections appears in Nat Med 2018;24:1292 and Nat Med 2018;24:1290]): 679-690
- Prognosticators of melanoma, the melanoma report, and the sentinel lymph node.Mod Pathol. 2006; 19: S71-S87
- Immunogenomic landscape of hematological malignancies [published correction appears in Cancer Cell 2020;28:424‒8.Cancer Cell. 2020; 38: 380-399.e13
- Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.Br J Dermatol. 2012; 167: 348-358
- PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.Blood. 2019; 133: 2279-2290
- T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.Science. 2017; 355: 1428-1433
- PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol. 2008; 26: 677-704
- A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging.Cell. 2018; 174 (e19): 1373-1387
- The immune landscape and response to immune checkpoint blockade therapy in lymphoma.Blood. 2020; 135: 523-533
- Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.Blood. 2011; 118: 5371-5379
- Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.J Immunol Methods. 2020; 478112714
- Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells.BMC Immunol. 2014; 15: 36
- Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing.J Invest Dermatol. 2017; 137: 1984-1994
- How do cytotoxic lymphocytes kill cancer cells?.Clin Cancer Res. 2015; 21: 5047-5056
- Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.Histopathology. 2019; 74: 1067-1080
- PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type.Am J Surg Pathol. 2018; 42: 326-334
- Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.Leukemia. 2004; 18: 589-596
- MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.J Invest Dermatol. 2012; 132: 2118-2120
- Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.Blood Adv. 2021; 5: 1816-1829
- Lymphocyte-mediated cytotoxicity.Annu Rev Immunol. 2002; 20: 323-370
- Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images.Cell Rep. 2018; 23: 181-193.e7
- Genetics and pathogenesis of diffuse large B-cell lymphoma.N Engl J Med. 2018; 378: 1396-1407
- Fluorochrome-labeled tyramides: use in immunocytochemistry and fluorescence in situ hybridization.J Histochem Cytochem. 1997; 45: 375-382
- A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.Mol Oncol. 2020; 14: 2384-2402
- The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood 2019;134:1112].Blood. 2019; 133: 1703-1714
- A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications.Cancer Cell. 2020; 37 (e14): 551-568
- Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type.J Invest Dermatol. 2018; 138: 2365‒76
Article info
Publication history
Published online: August 12, 2022
Accepted:
June 15,
2022
Received in revised form:
May 29,
2022
Received:
September 10,
2021
accepted manuscript published online 13 August 2022; corrected proof published online 30 September 2022Identification
Copyright
© 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
